These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 16635435

  • 1. Progressive multifocal leukoencephalopathy and multiple sclerosis: lessons from natalizumab.
    Langer-Gould A, Steinman L.
    Curr Neurol Neurosci Rep; 2006 May; 6(3):253-8. PubMed ID: 16635435
    [Abstract] [Full Text] [Related]

  • 2. Natalizumab treatment of multiple sclerosis: new insights.
    Delbue S, Comar M, Ferrante P.
    Immunotherapy; 2017 Jan; 9(2):157-171. PubMed ID: 28004598
    [Abstract] [Full Text] [Related]

  • 3. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE.
    Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
    [Abstract] [Full Text] [Related]

  • 4. Progressive multifocal leukoencephalopathy and natalizumab.
    Hellwig K, Gold R.
    J Neurol; 2011 Nov; 258(11):1920-8. PubMed ID: 21647730
    [Abstract] [Full Text] [Related]

  • 5. Asymptomatic reactivation of JC virus in patients treated with natalizumab.
    Chen Y, Bord E, Tompkins T, Miller J, Tan CS, Kinkel RP, Stein MC, Viscidi RP, Ngo LH, Koralnik IJ.
    N Engl J Med; 2009 Sep 10; 361(11):1067-74. PubMed ID: 19741227
    [Abstract] [Full Text] [Related]

  • 6. Natalizumab for relapsing remitting multiple sclerosis.
    Pucci E, Giuliani G, Solari A, Simi S, Minozzi S, Di Pietrantonj C, Galea I.
    Cochrane Database Syst Rev; 2011 Oct 05; (10):CD007621. PubMed ID: 21975773
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.
    Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, Curfman B, Miszkiel K, Mueller-Lenke N, Sanchez E, Barkhof F, Radue EW, Jäger HR, Clifford DB.
    N Engl J Med; 2006 Mar 02; 354(9):924-33. PubMed ID: 16510746
    [Abstract] [Full Text] [Related]

  • 8. Natalizumab in relapsing-remitting multiple sclerosis.
    Outteryck O.
    Expert Rev Neurother; 2016 May 02; 16(5):471-81. PubMed ID: 27008031
    [Abstract] [Full Text] [Related]

  • 9. Asymptomatic reactivation of JC virus in patients treated with natalizumab.
    Warnke C, Adams O, Kieseier BC.
    N Engl J Med; 2009 Dec 17; 361(25):2489; author reply 2489-90. PubMed ID: 20050216
    [No Abstract] [Full Text] [Related]

  • 10. John Cunningham Virus Status, Seroconversion Rate, and the Risk of Progressive Multifocal Leukoencephalopathy in Polish John Cunningham Virus-Seronegative Patients with Relapsing-Remitting Multiple Sclerosis.
    Kapica-Topczewska K, Collin F, Tarasiuk J, Czarnowska A, Chorąży M, Mirończuk A, Kochanowicz J, Kułakowska A.
    Eur Neurol; 2020 Dec 17; 83(5):487-492. PubMed ID: 33027785
    [Abstract] [Full Text] [Related]

  • 11. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.
    Kleinschmidt-DeMasters BK, Tyler KL.
    N Engl J Med; 2005 Jul 28; 353(4):369-74. PubMed ID: 15947079
    [Abstract] [Full Text] [Related]

  • 12. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

  • 13. Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.
    Ziemssen T, Gass A, Wuerfel J, Bayas A, Tackenberg B, Limmroth V, Linker R, Mäurer M, Haas J, Stangel M, Meergans M, Harlin O, Hartung HP.
    BMC Neurol; 2016 Jul 12; 16():98. PubMed ID: 27405225
    [Abstract] [Full Text] [Related]

  • 14. Natalizumab for relapsing-remitting multiple sclerosis.
    Horga A, Tintoré M.
    Neurologia; 2011 Jul 12; 26(6):357-68. PubMed ID: 21193250
    [Abstract] [Full Text] [Related]

  • 15. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.
    Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D.
    N Engl J Med; 2005 Jul 28; 353(4):375-81. PubMed ID: 15947078
    [Abstract] [Full Text] [Related]

  • 16. Natalizumab for relapsing multiple sclerosis.
    Tenser RB.
    N Engl J Med; 2006 Jun 01; 354(22):2387-9; author reply 2387-9. PubMed ID: 16738278
    [No Abstract] [Full Text] [Related]

  • 17. Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis.
    Lanza Cariccio V, Bramanti P, Mazzon E.
    Mult Scler Relat Disord; 2018 Feb 01; 20():93-99. PubMed ID: 29353737
    [Abstract] [Full Text] [Related]

  • 18. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring.
    Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A, Grigoriadis N, Hartung HP, Havrdová E, Hillert J, Hohlfeld R, Kremenchutzky M, Lyon-Caen O, Miller A, Pozzilli C, Ravnborg M, Saida T, Sindic C, Vass K, Clifford DB, Hauser S, Major EO, O'Connor PW, Weiner HL, Clanet M, Gold R, Hirsch HH, Radü EW, Sørensen PS, King J.
    Lancet Neurol; 2011 Aug 01; 10(8):745-58. PubMed ID: 21777829
    [Abstract] [Full Text] [Related]

  • 19. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis.
    Schröder A, Lee DH, Hellwig K, Lukas C, Linker RA, Gold R.
    Arch Neurol; 2010 Nov 01; 67(11):1391-4. PubMed ID: 20625069
    [Abstract] [Full Text] [Related]

  • 20. High cumulative JC virus seroconversion rate during long-term use of natalizumab.
    Vennegoor A, van Rossum JA, Leurs C, Wattjes MP, Rispens T, Murk JL, Uitdehaag BM, Killestein J.
    Eur J Neurol; 2016 Jun 01; 23(6):1079-85. PubMed ID: 27018481
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.